PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.10%
G&A change of 175.10% while TRVN maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-94.58%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-14.44%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-14.44%
Both companies reducing total costs. Martin Whitman would check industry trends.
4.10%
Interest expense growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Similar operating income growth to TRVN's 14.24%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.51%
Both companies reducing tax expense. Martin Whitman would check patterns.
12.51%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
12.37%
EPS growth while TRVN declines. John Neff would investigate advantages.
12.37%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.